- Home
- CWBC vs INBX Comparison
CWBC vs INBX Comparison
Compare CWBC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWBC | INBX |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | United States | United States |
| Employees | 338 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.9M | 1.1B |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | CWBC | INBX |
|---|---|---|
| Price | $23.50 | $76.23 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $24.33 | N/A |
| AVG Volume (30 Days) | ★ 169.2K | 139.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.05% | N/A |
| EPS Growth | N/A | ★ 649.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $200,000.00 |
| Revenue This Year | $39.39 | $563.00 |
| Revenue Next Year | $17.64 | N/A |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.57 | $10.81 |
| 52 Week High | $25.72 | $94.57 |
Technical Indicators
Market Signals| Indicator | CWBC | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 47.84 |
| Support Level | $20.34 | $72.13 |
| Resistance Level | $24.47 | $85.97 |
| Average True Range (ATR) | 0.71 | 5.15 |
| MACD | -0.18 | -0.62 |
| Stochastic Oscillator | 27.78 | 40.15 |
Price Performance
Historical ComparisonAbout CWBC Community West Bancshares
Community West Bancshares is a bank holding company whose principal business is to serve as the holding company for its wholly-owned subsidiary Community West Bank N.A. Through CWB, the Company provides a variety of financial products and full-service Banking Centers within California's Greater Sacramento, San Joaquin Valley, and Central Coast regions, that provide Commercial Lending, Real Estate, Agribusiness, Private Banking, and Cash Management Departments.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.